Eolo Pharma develops novel small molecules targeting inflammation-related diseases, with a focus on obesity and its comorbidities such as Type II diabetes and hypertension. Their lead compound, MVD-1, aims to enhance metabolic health by addressing the underlying mechanisms of obesity, thereby improving patient vitality and quality of life.
Funding
$7.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Obesity and its associated comorbidities, such as Type II diabetes, hypertension, and NASH, are a growing global health concern and a major driver of healthcare costs. Current treatments often fail to address the underlying mechanisms of metabolic dysfunction, leading to limited efficacy and potential side effects.
Solution
Eolo Pharma is developing novel small molecule therapeutics to combat obesity and related metabolic diseases. Their lead compound, MVD-1, is an orally available thermogenic new chemical entity (NCE) designed to enhance metabolic health by targeting the root causes of obesity. By addressing these underlying mechanisms, MVD-1 aims to improve patient vitality and overall quality of life. The company's NCE library consists of 60 novel molecules, including MVD-1 analogs and Eolo40, a compound targeting ALS and Alzheimer's disease by inhibiting NF-kB. Eolo Pharma has initiated Phase 1 clinical trials for MVD-1.
Target Audience
The primary target audience includes individuals with obesity and its associated comorbidities, such as Type II diabetes, hypertension, and NASH, as well as healthcare providers specializing in metabolic diseases.
Features
- Orally available thermogenic new chemical entity (NCE)
- Targets the underlying mechanisms of obesity and metabolic syndrome
- Designed to improve body weight, glucose levels, and overall metabolic health
- NCE library consisting of 60 novel molecules
- MVD-1 is currently in Phase 1 clinical trials
- Eolo40, a compound targeting ALS and Alzheimer's disease by inhibiting NF-kB